C Number:

Study Gender:

PWG Approval Date

PA10X: Statistical Analysis of Non-Neoplastic Lesions Test Compound: Sulfolane CAS Number: 126-33-0 Date Report Requested: 11/16/2018 Time Report Requested: 08:51:26 Lab: Battelle

C11054-03 Both See web page for date of PWG Approval

Male : Male Core										
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
Disposition Summary										
Animals Initially In Study	20	10	10	10	10	10	10			
Scheduled sacrifice, interim							2			
Early Deaths										
Euthanized, moribund							1			
Found Dead							7			
Scheduled Deaths										
Scheduled sacrifice, terminal (SD 29)	20	10	10	10	10	10				
Number of Animals Examined	20	10	10	10	10	10	10			

		Male : M	ale Core								
	Treatment Groups (mg/kg)										
	0	1	10	30	100	300	800				
ALIMENTARY SYSTEM											
ESOPHAGUS	(20)	(2)	(0)	(1)	(1)	(10)	(10)				
INFLAMMATION; CHRONIC	1 (5%) **	2 (100%)		1 (100%)	1 (100%)	1 (10%)	5 (50%) **				
INFLAMMATION; CHRONIC-ACTIVE							1 (10%)				
INFLAMMATION; GRANULOMATOUS	1 (5%)										
LIVER	(20)	(0)	(0)	(1)	(1)	(10)	(10)				
HEPATOCYTE; DEGENERATION	1 (5%)										
FIBROSIS	1 (5%)										
BILE DUCT; HYPERPLASIA	2 (10%)										
OVAL CELL; HYPERPLASIA	1 (5%)										
MINERAL	1 (5%)										
HEPATOCYTE; NECROSIS	5 (25%)			1 (100%)	1 (100%)	2 (20%)	1 (10%)				
PANCREAS	(20)	(0)	(0)	(0)	(0)	(10)	(10)				
ACINAR CELL; VACUOLATION	1 (5%)										
SALIVARY GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)				
LYMPHOCYTE; INFILTRATION, CELLULAR						1 (10%)					
STOMACH, GLANDULAR	(20)	(0)	(0)	(0)	(0)	(10)	(10)				
EROSION							1 (10%)				
NECROSIS							1 (10%)				
CARDIOVASCULAR SYSTEM											
HEART	(20)	(0)	(1)	(0)	(0)	(10)	(10)				
CARDIOMYOPATHY	4 (20%)						2 (20%)				
MYOCARDIUM; MINERAL							1 (10%)				
RHABDOMYOMATOSIS	5 (25%)					3 (30%)	2 (20%)				

	Male : Male Core									
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
ENDOCRINE SYSTEM										
PARATHYROID GLAND	(12)	(0)	(0)	(0)	(0)	(5)	(7)			
CYST; CONGENITAL							1 (14.3%			
PITUITARY GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
PARS DISTALIS; CYST; MULTIPLE						2 (20%)				
PARS DISTALIS; CYST	1 (5%)					1 (10%)				
THYROID GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
FOLLICLE; DILATION						1 (10%)				
GENERAL BODY SYSTEM										
None										
GENITAL SYSTEM										
TESTIS	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
GERM CELL; DEGENERATION						1 (10%)				
HEMATOPOIETIC SYSTEM										
THYMUS	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
NECROSIS							1 (10%)			
NTEGUMENTARY SYSTEM										
None										
LYMPHOID SYSTEM										
None										
MUSCULOSKELETAL SYSTEM										
None										

Male : Male Core										
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
NERVOUS SYSTEM										
None										
RESPIRATORY SYSTEM										
LUNGS CONGESTION	(20)	(0)	(0)	(0)	(0)	(10)	(10) 1 (10%)			
FOREIGN BODY HEMORRHAGE	4 (20%) 0 *					1 (10%)	2 (20%) 2 (20%)			
INFILTRATION, CELLULAR; HISTIOCYTE INFLAMMATION; CHRONIC	1 (5%) 1 (5%)					1 (10%)	_ (_0,/0)			
NOSE FOREIGN BODY	(20) 0 *	(0)	(0)	(0)	(0)	(10)	(10) 2 (20%)			
INFLAMMATION; CHRONIC-ACTIVE	9 (45%) *					6 (60%)	9 (90%) *			
TRACHEA INFLAMMATION	(20) 1 (5%)	(0)	(0)	(0)	(0)	(10)	(10)			
SPECIAL SENSES SYSTEM										
HARDERIAN GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
INFLAMMATION; CHRONIC-ACTIVE	7 (35%)					7 (70%)	2 (20%)			
URINARY SYSTEM										
KIDNEY	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
INFARCTION	1 (5%)									
RENAL TUBULE; REGENERATION	10 (50%)					5 (50%)	4 (40%)			

	Female : Female Core									
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
Disposition Summary							·			
Animals Initially In Study	20	10	10	10	10	10	10			
Scheduled sacrifice, interim							7			
Early Deaths										
Found Dead							3			
Scheduled Deaths										
Scheduled sacrifice, terminal (SD 29)	20	10	10	10	10	10				
Number of Animals Examined	20	10	10	10	10	10	10			
ALIMENTARY SYSTEM										
ESOPHAGUS	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
INFLAMMATION; CHRONIC	0 **						5 (50%) **			
INTESTINE, SMALL, JEJUNUM	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
CONGESTION							1 (10%)			
LIVER	(20)	(3)	(6)	(3)	(1)	(10)	(10)			
HEPATOCYTE; NECROSIS	9 (45%)	2 (66.7%)	6 (100%)	3 (100%)	1 (100%)	2 (20%)	3 (30%)			
CARDIOVASCULAR SYSTEM										
HEART	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
CARDIOMYOPATHY	5 (25%)					1 (10%)	2 (20%)			
ENDOCARDIUM; HYPERPLASIA; ENDOTHELIAL							1 (10%)			
INFLAMMATION; ACUTE							1 (10%)			
RHABDOMYOMATOSIS	7 (35%)					0 *	2 (20%)			

	Female : Female Core									
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
ENDOCRINE SYSTEM										
ADRENAL GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
CORTEX; CYST						. ,	1 (10%)			
CORTEX; HYPERPLASIA; FOCAL	1 (5%)						•			
PARATHYROID GLAND	(10)	(0)	(0)	(0)	(0)	(5)	(8)			
CYST; CONGENITAL	1 (10%)			. ,						
PITUITARY GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
PARS DISTALIS; CYST; MULTIPLE						. ,	1 (10%)			
PARS DISTALIS; CYST	1 (5%)					1 (10%)	•			
PARS INTERMEDIA; CYST						2 (20%)				
THYROID GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
FOLLICLE; DILATION							1 (10%			
INFLAMMATION; CHRONIC						1 (10%)				
GENERAL BODY SYSTEM										
None										
GENITAL SYSTEM										
CERVIX	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
ANGIECTASIS; FOCAL						1 (10%)				
HEMATOPOIETIC SYSTEM										
None										
INTEGUMENTARY SYSTEM										
None										
LYMPHOID SYSTEM										
None										

Test Type: TOX Route: Oral Gavage Species/Strain: Guinea Pig/Hartley			ompound: Sulfolane Number: 126-33-0			Time Report Requested: 08:51:26 Lab: Battelle				
		Female :	Female Core							
	Treatment Groups (mg/kg)									
	0	1	10	30	100	300	800			
MUSCULOSKELETAL SYSTEM None										
NERVOUS SYSTEM None										
RESPIRATORY SYSTEM										
LUNGS	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
FOREIGN BODY	5 (25%)					2 (20%)				
HEMORRHAGE	0 *						2 (20%)			
ALVEOLAR EPITHELIUM; HYPERPLASIA	1 (5%)					4 (400()				
INFILTRATION, CELLULAR; HISTIOCYTE INFLAMMATION; CHRONIC	3 (15%)					1 (10%) 2 (20%)	2 (20%)			
NOSE	(20)	(10)	(10)	(10)	(10)	(10)	2 (20%) (10)			
INFLAMMATION; CHRONIC-ACTIVE	20 (100%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)	. ,	10 (100%)			
SPECIAL SENSES SYSTEM										
HARDERIAN GLAND	(20)	(0)	(0)	(0)	(0)	(10)	(10)			
INFLAMMATION; CHRONIC-ACTIVE	1 (5%)						1 (10%)			
URINARY SYSTEM										
KIDNEY	(20)	(0)	(1)	(0)	(0)	(10)	(10)			
			4 (4 9 9 9 ()							

PA10X: Statistical Analysis of Non-Neoplastic Lesions

Date Report Requested: 11/16/2018

7 (70%)

7 (70%)

Study Number: C11054-03

PELVIS; DILATION

RENAL TUBULE; REGENERATION

17 (85%)

1 (100%)

Date Report Requested: 11/16/2018 Time Report Requested: 08:51:26 Lab: Battelle

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical analysis is performed for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

Trend p-values are reported only for those organs that were fully examined in the control group plus two or more other dose groups. For organs that were fully examined in just the control and one other dose group, only the pairwise p-values are reported.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

All trend and pairwise p-values are reported as one-sided.

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

** END OF REPORT **